Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes.

MLA

Magro, Fernando, et al. “Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes.” Journal of Crohn’s & Colitis, vol. 17, no. 9, Oct. 2023, pp. 1457–70. EBSCOhost, https://doi.org/10.1093/ecco-jcc/jjad050.

APA

Magro, F., Pai, R. K., Kobayashi, T., Jairath, V., Rieder, F., Redondo, I., Lissoos, T., Morris, N., Shan, M., Park, M., & Peyrin-Biroulet, L. (2023). Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes. Journal of Crohn’s & Colitis, 17(9), 1457–1470. https://doi.org/10.1093/ecco-jcc/jjad050

Chicago

Magro, Fernando, Rish K Pai, Taku Kobayashi, Vipul Jairath, Florian Rieder, Isabel Redondo, Trevor Lissoos, et al. 2023. “Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes.” Journal of Crohn’s & Colitis 17 (9): 1457–70. doi:10.1093/ecco-jcc/jjad050.